Endo, Novartis begin agreement

Share this article:

Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for Voltaren Gel (diclofenac sodium topical gel) 1%. Endo said it expects to commercialize Voltaren Gel using one of its two specialty sales forces, consisting of 160 reps, prior to executing a full physician launch in late May with an additional 275 contract sales reps targeting primary care physicians who prescribe both NSAIDs and Cox-2s.

Voltaren Gel received FDA approval in October 2007. Endo estimates US peak annual sales for Voltaren Gel as an osteoarthritis pain treatment in the range of $250-300 million. 
Share this article:
You must be a registered member of MMM to post a comment.

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters